Posted by Michael Wonder on 12 Jun 2017
NHS Scotland reject ‘extremely effective’ breast cancer drug for third time despite drug being offered to English patients
12 June 2017 - The Scottish Medicines Consortium said that they don't believe Perjeta would be a 'good use of limited NHS resources'.
NHS Scotland have rejected an “extremely effective” breast cancer treatment for the third time despite the drug being offered to patients in England.
Campaigners have branded the decision as a “huge blow” as manufacturers Roche claim that the drug, also known as pertuzumab, can extend the life of patients with advanced breast cancer by almost 16 months.
